Loading...

INBX INHIBRX BIOSCIENCES INC Product Launches 8-K Filing

NHBR

NBX

INHIBRX BIOSCIENCES INC

(INBX)

2025 8-K

Financial Results Announced

Clinical Trial Update

Clinical Data Update

Financial Results Announcement

Corporate Presentation Update

Clinical Trial Update

Financial Results Announced

Positive Trial Results

Financial Results Announcement

Financial Statements

Management Changes

Financial Results

Ozekibart Data Release

Financial Results

External Links:

Inhibrx Biosciences announced preliminary data from a Phase 1 trial of ozekibart for treating advanced colorectal cancer, showing one complete response, three partial responses, and a median progression-free survival of 7.85 months among patients.

AI Assistant

INHIBRX BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.